Moreover, circulating levels of PCSK9 of <95 ng/mL during the second cycle of nivolumab treatment could independently predict a better overall survival in elderly patients with advanced, pretreated NSCLC (40). The gene discussed is PCSK9; the disease is non-small cell lung carcinoma.